Home LiteratureArticle Details
PMID: 19451418 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 27 ·No. 18 ·2009-06-20 ·Pages 2905-8

van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM

Abstract

Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.

MeSH Terms
Brain Neoplasms/therapy Disease Progression Glioma/therapy Humans Randomized Controlled Trials as Topic Research Design
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
van den Bent Martin J
Neuro-Oncology Unit, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands.
Vogelbaum Michael A
Wen Patrick Y
Macdonald David R
Chang Susan M
References (38)
38 references, click to expand
  1. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection.
    J Neurosurg. 1996 Feb;84(2):174-9 PMID: 8592218
  2. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
    J Clin Oncol. 2004 Aug 1;22(15):3133-8 PMID: 15284265
  3. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Ann Oncol. 2003 Dec;14(12):1715-21 PMID: 14630674
  4. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
    Cancer. 2008 Jul 15;113(2):405-10 PMID: 18484594
  5. MR of recurrent high-grade astrocytomas after intralesional immunotherapy.
    AJNR Am J Neuroradiol. 1996 Jun-Jul;17(6):1065-71 PMID: 8791917
  6. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
    J Neurooncol. 2007 Mar;82(1):81-3 PMID: 16944309
  7. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
    Neuro Oncol. 2007 Jan;9(1):29-38 PMID: 17108063
  8. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
    J Neurosurg. 2005 Feb;102(2):267-75 PMID: 15739554
  9. Transient postictal MRI changes in patients with brain tumors may mimic disease progression.
    Surg Neurol. 2007 Mar;67(3):246-50; discussion 250 PMID: 17320628
  10. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    J Clin Oncol. 2008 Oct 1;26(28):4659-65 PMID: 18824712
  11. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    J Nucl Med. 2006 Jun;47(6):904-11 PMID: 16741298
  12. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    J Clin Oncol. 2006 Jun 20;24(18):2715-22 PMID: 16782911
  13. CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.
    AJNR Am J Neuroradiol. 2004 Aug;25(7):1211-7 PMID: 15313712
  14. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma.
    J Clin Oncol. 1994 Sep;12(9):1886-9 PMID: 8083712
  15. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
    J Clin Oncol. 1999 Aug;17(8):2572-8 PMID: 10561324
  16. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    J Clin Oncol. 2006 Jun 20;24(18):2707-14 PMID: 16782910
  17. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    J Clin Oncol. 2007 Oct 20;25(30):4722-9 PMID: 17947719
  18. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
    Lancet Oncol. 2006 May;7(5):392-401 PMID: 16648043
  19. Postoperative changes in the brain: MR imaging findings in patients without neoplasms.
    Radiology. 1997 Sep;204(3):839-46 PMID: 9280269
  20. Brain tumor imaging in clinical trials.
    AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 PMID: 18272557
  21. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
    Lancet. 2005 Sep 17-23;366(9490):985-90 PMID: 16168780
  22. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    J Clin Oncol. 2007 Oct 20;25(30):4714-21 PMID: 17947718
  23. Steroid-induced CT changes in patients with recurrent malignant glioma.
    Neurology. 1988 May;38(5):724-6 PMID: 3362369
  24. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
    Cancer Cell. 2007 Jan;11(1):83-95 PMID: 17222792
  25. Response criteria for phase II studies of supratentorial malignant glioma.
    J Clin Oncol. 1990 Jul;8(7):1277-80 PMID: 2358840
  26. MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.
    AJNR Am J Neuroradiol. 2001 Sep;22(8):1517-27 PMID: 11559499
  27. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
    Neuro Oncol. 2008 Apr;10(2):162-70 PMID: 18356283
  28. Brachytherapy for recurrent malignant astrocytoma.
    Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1213-7 PMID: 7961031
  29. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Cancer. 2005 Feb 15;103(4):802-9 PMID: 15637687
  30. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.
    Radiology. 2000 Nov;217(2):377-84 PMID: 11058631
  31. Postoperative contrast enhancement in patients with brain tumor.
    Ann Neurol. 1985 Jun;17(6):570-2 PMID: 4026227
  32. Continuous growth of mean tumor diameter in a subset of grade II gliomas.
    Ann Neurol. 2003 Apr;53(4):524-8 PMID: 12666121
  33. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Neurology. 2008 Mar 4;70(10):779-87 PMID: 18316689
  34. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
    Neurology. 2004 Aug 10;63(3):535-7 PMID: 15304589
  35. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.
    J Neurosurg. 2005 Sep;103(3):428-38 PMID: 16235673
  36. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.
    Neurology. 2006 Nov 14;67(9):1668-70 PMID: 17101902
  37. Response criteria for glioma.
    Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 PMID: 18711427
  38. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    J Clin Oncol. 2008 May 1;26(13):2192-7 PMID: 18445844
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
DOI
10.1200/JCO.2009.22.4998
Published
2009-06-20
Epub
2009-00-18
Pages
2905-8
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC2702230
Subset
IM
Grants
NCI NIH HHS · P01 CA118816 · United States
External Links
PubMed source DOI: 10.1200/JCO.2009.22.4998 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2